Moberg Pharma and Colep Enters Development Agreement
News Nov 06, 2015
Moberg Pharma AB has announced that Moberg Pharma and Colep have entered a Development Agreement for MOB-015 – a novel topical formulation of terbinafine for onychomycosis (nail fungus).
Under the agreement, Colep’s Healthcare Division will share funding by conducting a pharmaceutical development program which will include scale-up of manufacturing processes, stability programs and supply of clinical trial material for the Phase 3 program for MOB-015 as well as the documentation required to file for marketing authorization in the U.S. and EU.
Moberg has appointed Colep the exclusive commercial supplier of MOB-015 for the agreed territories. Moberg will own all data and documentation generated from the pharmaceutical development program and plans to initiate a clinical phase 3 program in 2016.
The parties will enter a supply agreement for a subsequent commercial phase building on synergies from other products that Colep currently manufactures for Moberg. Financial terms were not disclosed.
“We are excited to further build on the synergies being generated from our current collaboration with Colep. This agreement leverages Colep’s expertise and manufacturing capabilities for the late-stage development and subsequent commercialization of MOB-015. For Moberg, this agreement reduces our development expenses for phase 3 and establishes an attractive supply cost for the commercial phase. Forming innovative partnership models supports Moberg’s commitment to bringing novel treatments to patients in underserved niches, and further advances our vision to become the leading player in onychomycosis,” said Peter Wolpert, CEO of Moberg Pharma AB.
“We are delighted to expand our successful collaboration with Moberg Pharma to now include MOB-015. We decided to co-invest in the project based on the significant market potential for MOB-015 as well as the strong track record established by the other Moberg products Colep currently manufactures“, said Ludwig Bastiaansen, Managing Director, Healthcare Division, Colep.
Colep Healthcare Division provides dedicated manufacturing (filling and packing) capabilities, for pharmaceuticals, medical devices and high-end applications.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018